1 / 6

Radiation Therapy Connective Tissue Oncology Society 2005

Radiation Therapy Connective Tissue Oncology Society 2005. Thomas F. DeLaney, M.D. Samarium-153 for Osteosarcoma. Anderson PM (Mayo Clinic) 14 patients High dose samarium 30 mCi/kg + gemcitabine 1500 mg/m2 Stem cells reinfused 2 weeks later

emilie
Download Presentation

Radiation Therapy Connective Tissue Oncology Society 2005

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Radiation TherapyConnective Tissue Oncology Society 2005 Thomas F. DeLaney, M.D.

  2. Samarium-153 for Osteosarcoma • Anderson PM (Mayo Clinic) • 14 patients • High dose samarium 30 mCi/kg + gemcitabine 1500 mg/m2 • Stem cells reinfused 2 weeks later • Standard dose samarium 1 mCi/kg + gemcitabine 1000 mg/m2 repeated in respondersa • Toxicity • Modest cytopenias • Responses • 6 PR, 2 mixed, 6 progressive • All relapsed or had new metastases within a year • ? Use standard dose samarium + gemcitabine for multiple cycles and combine with external beam, avastin, HDMTX

  3. STS-Results of Limb Sparing Therapy • Merimsky O et al (Tel Aviv Medical Center) • 133 patients • Intermediate and high grade sarcomas • Limb sparing surgery + post-op XRT • Results • 23 LR; 35 systemic spread +/- LR • DFS/OS influenced by: • Stage I (A or B) vs Stage II • Upper vs lower limb • Resection margins: adequate vs marginal/positive margins • Good vs bad histologic response to induction therapy • If diagnostic biopsy at outside facility, fare worse • MFH : 10 y RFS: 62%- relapses occur in first 3 years • Liposarcoma: 10 Y RFS 52%; relapses occurring out to 8 years

  4. Retroperitoneal STS: Surgery + XRT +/- Chemotherapy • Ballo et al (MD Ancerson Cancer Center) • 84 patients (1965-2003) with primary (61)/LR (23) STS • G1 13 G2 19 G3 52 • Margins Positive/Uncertain 40 Negative 44 • EBRT only 64 pts (40-66 Gy; Median 50 Gy) Post-op 33 pts • EBRT + IORT 18 pts; IORT (10-15 Gy; Median 15 Gy) • DSS 47% DMFS 66% LC 51% • LF: 29/33 in field; 2/33 marginal; 2 /33 outside • Multivariate: G3 : inferior DFS 36 % vs 64% • Local control • Inferior in pts presenting with recurrent disease : 35% vs 58% • Inferior for positive/uncertain margins 34% vs. 69% for (-) margins • Not improved with  dose, IORT, concurrent chemoRx, XRT timing • Complications • 11% at 5 years ; these patients received post-op XRT

  5. Radio-Hyperthermo-ChemoRx for MFH • Marsushita Y et al (Nagoya City Univ. Medical School) • 34 pts with MFH (1992-2000) • XRT: 32 Gy/16 fx of 2 Gy q.d. • Hyperthermia Weekly x 5 sessions: 42.5° for > 60 min • Cisplatin 90 mg/m2 and Pinorubin 25 mg/m2 i.a. q week x 3 • Surgical margin: wide 12 pts; marginal 20 pts: 2 LR • 21 pts CDF; 5 NED; 5 DOD; 1 AWD; 3 DID • Complications: Deaths: 1 septicemia, 1 PE • 2 2nd degree burns • 8 delayed wound healing

  6. Complications of Combined Modality Therapy for Lower Extremity STS • Cannon et al (MD Anderson Cancer Center) • 412 pts with primary LE STS • Pre-op XRT 268 (65%): median dose of 50 Gy • Post-op XRT 144 (35%): median dose of 60 Gy • Complications • Acute wound: 15%: no difference pre vs post-op XRT • Medial thigh vs non medial: 21% vs 8 % • Chronic complications: 6% • Post-op 16% vs Pre-op 6% p=0.02 • Thigh fractures: Peri-osteal stripping 10% vs. no stripping 1%

More Related